ArticleNPJ breast cancer2026
Risk factors and metastatic sites in HER2-positive breast cancer with pathological complete response.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is associated with favorable outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer; however, brain metastases still occur. Using the National Clinical Database-Breast Cancer Registry (JAPAN 2008-2020), we identified 21,494 patients who received NAC followed by surgery. After excluding cases without pCR status or prognostic data, 8421 patients were analyzed (2430 pCR; 5991 non-pCR). Disease-free survival (DFS), brain metastasis-free survival, and recurrence patterns were compared, and risk factors for distant recurrence were evaluated. Patients achieving pCR had significantly better 5-year DFS than non-pCR patients. Among pCR cases, hormone receptor status and clinical stage independently predicted recurrence. At 5 years, brain metastases occurred in 2.6% of pCR patients and 4.5% of non-pCR patients. These findings indicate that pCR does not eliminate the risk of brain metastases, highlighting the need for continued vigilance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.